GO:0035249 synaptic transmission, glutamatergic: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035249 describes the vesicular release of glutamate from a presynapse, activation of postsynaptic glutamate receptors, and the resulting changes in postsynaptic membrane potential and ionic composition.
• Glutamatergic synaptic transmission is the principal excitatory signaling mechanism in the mammalian brain and is impaired in Alzheimer's disease, phenylketonuria, and other neurological conditions.
• Developmental maturation of glutamatergic transmission in motor cortex layer II/III pyramidal neurons is critical for circuit formation and motor function.
• Inflammatory signals such as bacterial endotoxin lipopolysaccharide can enhance synaptic transmission at low-output glutamatergic synapses, linking immune activation to altered excitability.
• Neuromodulators including ketamine and stress-related peptides disrupt or modulate glutamatergic synaptic transmission in brain regions such as the bed nucleus of the stria terminalis.
• RhoGEF Tiam2 regulates glutamatergic synaptic transmission in hippocampal CA1 pyramidal neurons, illustrating the role of cytoskeletal signaling in synaptic efficacy.
Description
Glutamatergic synaptic transmission (GO:0035249) is the fundamental excitatory communication process in the nervous system, encompassing the vesicular release of glutamate from a presynaptic terminal, the activation of glutamate receptors on the postsynaptic membrane, and the downstream effects on membrane potential and ionic composition. This process underlies rapid information transfer in neural circuits and is essential for sensory processing, motor control, learning, and memory. Disruptions in glutamatergic signaling are increasingly recognized as central to the pathophysiology of numerous neurological and psychiatric disorders, including Alzheimer's disease, phenylketonuria, and stress-related conditions. Researchers study this term to understand normal brain function and to identify therapeutic targets for diseases characterized by excitatory/inhibitory imbalance. The process is highly regulated across development and by neuromodulatory systems, making it a rich area for genetic and pharmacological investigation.
synaptic transmission, glutamatergic At A Glance
| GO ID | GO:0035249 |
|---|---|
| GO term | synaptic transmission, glutamatergic |
| Ontology | biological_process |
| Synonym | glutamatergic synaptic transmission |
| Major function | Excitatory synaptic transmission via glutamate release and receptor activation |
| Definition source | QuickGO |
| Related cellular components | Presynaptic terminal, synaptic vesicle, postsynaptic density, glutamate receptors |
| Related molecular functions | Glutamate receptor activity, vesicle fusion, neurotransmitter transporter activity |
What Is GO:0035249?
According to the Gene Ontology, GO:0035249 (synaptic transmission, glutamatergic) is defined as the vesicular release of glutamate from a presynapse, across a chemical synapse, followed by activation of glutamate receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process includes both spontaneous and evoked neurotransmitter release and all parts of synaptic vesicle exocytosis. Evoked transmission begins with the arrival of an action potential at the presynapse.
Why Is synaptic transmission, glutamatergic Important in Cell Biology?
Glutamatergic synaptic transmission is the primary excitatory signaling pathway in the mammalian central nervous system and is essential for virtually all brain functions, from sensory perception to memory formation. Its dysfunction is implicated in a wide range of disorders, including Alzheimer's disease, phenylketonuria, and stress-related psychiatric conditions. Understanding the molecular and cellular mechanisms of this process is therefore critical for developing targeted therapies and for interpreting genetic and pharmacological data in neuroscience research.
• Underlies fast excitatory neurotransmission in the brain and spinal cord.
• Impaired in Alzheimer's disease, contributing to cognitive decline.
• Dysregulated in phenylketonuria, leading to neurological deficits.
• Shows developmental changes in motor cortex that are critical for circuit maturation.
• Modulated by inflammatory signals such as lipopolysaccharide.
• Disrupted by ketamine, a drug used to model psychosis and depression.
• Regulated by stress-related peptides in the bed nucleus of the stria terminalis.
• Controlled by RhoGEF Tiam2 in hippocampal CA1 neurons, linking cytoskeletal dynamics to synaptic strength.
• A key target for neuroprotective strategies, including N-acetylcysteine.
• Central to understanding excitatory/inhibitory balance in health and disease.
What Happens During synaptic transmission, glutamatergic?
Vesicular glutamate release
In simple terms: Glutamate is packaged into small bubbles called vesicles and released from the presynaptic neuron.
Glutamate is loaded into synaptic vesicles by vesicular glutamate transporters and released into the synaptic cleft upon calcium influx triggered by an action potential. This vesicular release is a defining step of GO:0035249 and is required for both spontaneous and evoked transmission.
Postsynaptic receptor activation
In simple terms: Glutamate binds to receptors on the receiving neuron, causing ions to flow.
Once in the cleft, glutamate binds to ionotropic receptors such as AMPA and NMDA receptors and to metabotropic glutamate receptors on the postsynaptic membrane. This activation leads to ion flux and changes in the postsynaptic membrane potential and ionic composition, as specified in the GO definition.
Developmental and activity-dependent changes
In simple terms: The strength of glutamatergic transmission changes as the brain develops and with experience.
During development, glutamatergic synaptic transmission in layer II/III mouse motor cortex pyramidal neurons increases, reflecting maturation of excitatory circuits. Activity-dependent plasticity further modifies synaptic strength, which is essential for learning and memory.
Neuromodulation and inflammatory modulation
In simple terms: Other signals can turn glutamatergic transmission up or down.
Neuromodulators such as ketamine disrupt neuromodulatory control of glutamatergic synaptic transmission, while stress-related peptides modulate transmission in the bed nucleus of the stria terminalis. Inflammatory stimuli like lipopolysaccharide can enhance synaptic transmission at low-output glutamatergic synapses, demonstrating that immune signals intersect with glutamatergic signaling.
Cytoskeletal regulation
In simple terms: Proteins that control cell shape can also control synaptic strength.
The RhoGEF Tiam2 regulates glutamatergic synaptic transmission in hippocampal CA1 pyramidal neurons, highlighting a role for actin cytoskeleton dynamics in synaptic efficacy.
Key Genes Involved in GO:0035249 synaptic transmission, glutamatergic
The following genes and proteins are experimentally implicated in glutamatergic synaptic transmission (GO:0035249) based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GRIN1 | NMDA receptor subunit | Mediates postsynaptic calcium influx; target in Alzheimer's disease models |
| GRIN2A | NMDA receptor subunit | Modulates synaptic plasticity; implicated in neurodevelopmental disorders |
| GRIA1 | AMPA receptor subunit | Mediates fast excitatory transmission; studied in motor cortex development |
| GRIA2 | AMPA receptor subunit | Controls calcium permeability; relevant to excitotoxicity |
| GRM1 | Metabotropic glutamate receptor | Modulates synaptic transmission via G-protein signaling |
| SLC17A7 | Vesicular glutamate transporter 1 | Packages glutamate into vesicles; essential for release |
| SLC17A6 | Vesicular glutamate transporter 2 | Packages glutamate into vesicles in subcortical regions |
| SLC1A2 | Glutamate transporter (EAAT2) | Clears glutamate from cleft; prevents excitotoxicity |
| SLC1A3 | Glutamate transporter (EAAT1) | Regulates extracellular glutamate levels |
| TIAM2 | RhoGEF | Regulates glutamatergic transmission in hippocampal CA1 neurons |
| DLG4 | Postsynaptic density protein 95 | Scaffolds glutamate receptors; modulates synaptic strength |
| CAMK2A | Calcium/calmodulin-dependent kinase II | Mediates activity-dependent synaptic plasticity |
| BDNF | Neurotrophic factor | Enhances glutamatergic transmission; linked to plasticity |
| GRIN2B | NMDA receptor subunit | Involved in developmental synaptic maturation |
| HOMER1 | Postsynaptic scaffold | Regulates metabotropic glutamate receptor signaling |
| SHANK3 | Postsynaptic scaffold | Organizes glutamate receptor complexes; linked to autism |
| ARC | Activity-regulated cytoskeleton-associated protein | Required for synaptic plasticity and AMPA receptor trafficking |
How Is synaptic transmission, glutamatergic Regulated?
Glutamatergic synaptic transmission is regulated at multiple levels, including presynaptic release probability, postsynaptic receptor trafficking, and neuromodulatory inputs. Ketamine disrupts neuromodulatory control of glutamatergic synaptic transmission, indicating that monoaminergic and cholinergic systems influence this process. Stress-related peptides modulate transmission in the bed nucleus of the stria terminalis. Inflammatory mediators such as lipopolysaccharide can enhance synaptic transmission at low-output glutamatergic synapses. Additionally, the RhoGEF Tiam2 regulates glutamatergic synaptic transmission in hippocampal CA1 pyramidal neurons, linking cytoskeletal dynamics to synaptic efficacy. Neuroprotective agents like N-acetylcysteine modulate glutamatergic transmission and restore synaptic plasticity.
synaptic transmission, glutamatergic and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GRIN1 | Alzheimer's disease | Knockout or point-mutation in mouse models to study NMDA receptor dysfunction |
| GRIA1 | Motor cortex development | Knock-in of tagged AMPA receptor to track trafficking in layer II/III neurons |
| TIAM2 | Hippocampal synaptic transmission | Knockout in CA1 pyramidal neurons to assess synaptic efficacy |
| SLC17A7 | Glutamate release | Conditional knockout to study vesicular release in vivo |
| GRM1 | Stress-related disorders | Overexpression in bed nucleus of the stria terminalis to model anxiety |
Alzheimer's disease
Impairments of glutamatergic synaptic transmission are a hallmark of Alzheimer's disease and contribute to cognitive decline. Studies in animal models and human tissue show disrupted glutamate release and receptor function.
Phenylketonuria (PKU)
In the PKU brain, impaired glutamatergic synaptic transmission is observed, likely due to elevated phenylalanine levels that interfere with neurotransmitter homeostasis.
Psychiatric and stress-related disorders
Ketamine, used to model psychosis and depression, disrupts neuromodulatory control of glutamatergic synaptic transmission. Stress-related peptides modulate transmission in the bed nucleus of the stria terminalis, a region implicated in anxiety and addiction.
Neuroinflammation
Bacterial endotoxin lipopolysaccharide enhances synaptic transmission at low-output glutamatergic synapses, suggesting that systemic inflammation can alter glutamatergic signaling and contribute to neuropsychiatric symptoms.
From synaptic transmission, glutamatergic-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene regulate glutamate release? | Knockout of vesicular transporter or release machinery in primary neurons |
| How does a point mutation in a glutamate receptor affect synaptic currents? | Point-mutation knock-in in mice followed by electrophysiology |
| Where is a synaptic protein localized? | Knock-in of fluorescent tag (e.g., GFP) at endogenous locus |
| Does overexpression of a scaffold protein alter synaptic strength? | Overexpression via viral vectors in hippocampal slices |
| What is the role of a gene in developmental maturation of glutamatergic transmission? | Conditional knockout during critical periods in motor cortex |
| How does inflammation modulate glutamatergic synapses? | Lipopolysaccharide treatment in low-output synapse models |
How to Study the synaptic transmission, glutamatergic Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Postsynaptic currents and membrane potential | Quantify synaptic strength in knockout or mutant mice |
| iGluSnFR imaging | Glutamate release events | Visualize presynaptic release probability |
| CRISPR knockout | Loss-of-function effects | Identify genes required for glutamatergic transmission |
| CRISPR knock-in | Tagged protein localization | Track receptor trafficking in vivo |
| RNA-seq | Transcriptional changes | Assess gene expression after manipulation |
| Western blot | Protein levels | Validate knockout or overexpression |
| Immunohistochemistry | Synaptic protein localization | Map distribution of glutamate receptors |
| Behavioral assays | Cognitive and motor function | Link synaptic changes to behavior |
Electrophysiology
Patch-clamp recordings measure spontaneous and evoked excitatory postsynaptic currents (EPSCs) to quantify glutamatergic synaptic transmission strength and kinetics.
Fluorescence imaging
Live-cell imaging with pH-sensitive or fluorescent glutamate sensors (e.g., iGluSnFR) visualizes vesicular release and glutamate dynamics at individual synapses.
Genetic manipulation and CRISPR screening
CRISPR knockout or knock-in of candidate genes followed by functional assays identifies regulators of glutamatergic transmission.
Pharmacological and optogenetic tools
Application of receptor agonists/antagonists (e.g., ketamine, NBQX) and optogenetic stimulation of glutamatergic neurons dissects pathway-specific contributions.
How CRISPR Can Be Used to Study GO:0035249 synaptic transmission, glutamatergic
Knockout
CRISPR knockout of genes such as GRIN1, GRIA1, or TIAM2 in cell lines or primary neurons can reveal their requirement for glutamatergic synaptic transmission. For example, Tiam2 knockout in hippocampal CA1 neurons alters synaptic efficacy.
Point Mutation
Introducing disease-associated point mutations (e.g., in GRIN2A or GRIA2) via CRISPR base editing or homology-directed repair allows precise modeling of receptor dysfunction and its impact on synaptic currents.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags at endogenous loci enables real-time tracking of glutamate receptors and vesicle proteins in living neurons.
Overexpression
CRISPR activation (CRISPRa) or viral overexpression of genes like BDNF or SHANK3 can enhance glutamatergic transmission and model gain-of-function states.
How EDITGENE Supports synaptic transmission, glutamatergic Research
Researchers studying synaptic transmission, glutamatergic-related genes often need to determine whether a candidate gene is causally involved in glutamate release, receptor function, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional interrogation of GO:0035249.
Contact EDITGENE today to design your custom CRISPR model for synaptic transmission, glutamatergic research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GRIN2B Knockout HEK293 Cell Line | EDJ-KQ668 | Human | 2904 | Details Get a Quote |
| GRIN3B Knockout HEK293 Cell Line | EDJ-KQ1135 | Human | 116444 | Details Get a Quote |
| GRIN2A Knockout HEK293 Cell Line | EDJ-KQ1220 | Human | 2903 | Details Get a Quote |
| ADORA2A Knockout HEK293 Cell Line | EDJ-KQ1290 | Human | 135 | Details Get a Quote |
| P2RX1 Knockout HEK293 Cell Line | EDJ-KQ1570 | Human | 5023 | Details Get a Quote |
| GRIN2C Knockout HEK293 Cell Line | EDJ-KQ1576 | Human | 2905 | Details Get a Quote |
| GRIN2D Knockout HEK293 Cell Line | EDJ-KQ1577 | Human | 2906 | Details Get a Quote |
| GRIN3A Knockout HEK293 Cell Line | EDJ-KQ1814 | Human | 116443 | Details Get a Quote |
| GRIA1 Knockout HEK293 Cell Line | EDJ-KQ1815 | Human | 2890 | Details Get a Quote |
| GRIA2 Knockout HEK293 Cell Line | EDJ-KQ1816 | Human | 2891 | Details Get a Quote |
| GRIA3 Knockout HEK293 Cell Line | EDJ-KQ1817 | Human | 2892 | Details Get a Quote |
| GRIA4 Knockout HEK293 Cell Line | EDJ-KQ1818 | Human | 2893 | Details Get a Quote |
| SLC1A4 Knockout HEK293 Cell Line | EDJ-KQ2483 | Human | 6509 | Details Get a Quote |
| GRIK1 Knockout HEK293 Cell Line | EDJ-KQ3135 | Human | 2897 | Details Get a Quote |
| SLC17A8 Knockout HEK293 Cell Line | EDJ-KQ3835 | Human | 246213 | Details Get a Quote |
Displaying Records 1 To 15 Of 123 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About synaptic transmission, glutamatergic
What is GO:0035249?
GO:0035249 is the Gene Ontology term for synaptic transmission, glutamatergic, defined as the vesicular release of glutamate from a presynapse, activation of postsynaptic glutamate receptors, and the resulting effects on the postsynaptic membrane potential and ionic composition.
What genes are involved in glutamatergic synaptic transmission?
Key genes include GRIN1, GRIN2A, GRIA1, GRIA2, SLC17A7, SLC1A2, TIAM2, DLG4, and CAMK2A, among others.
How is glutamatergic synaptic transmission impaired in Alzheimer's disease?
Alzheimer's disease involves impairments in glutamatergic synaptic transmission, including disrupted glutamate release and receptor function, which contribute to cognitive decline.
What is the role of ketamine in glutamatergic transmission?
Ketamine disrupts neuromodulatory control of glutamatergic synaptic transmission, which is relevant to its psychotomimetic and antidepressant effects.
Can inflammation affect glutamatergic synapses?
Yes, bacterial endotoxin lipopolysaccharide enhances synaptic transmission at low-output glutamatergic synapses, linking inflammation to altered excitability.
How does Tiam2 regulate glutamatergic transmission?
RhoGEF Tiam2 regulates glutamatergic synaptic transmission in hippocampal CA1 pyramidal neurons, likely through cytoskeletal remodeling.
What methods are used to study glutamatergic synaptic transmission?
Common methods include patch-clamp electrophysiology, fluorescence imaging with glutamate sensors, CRISPR knockout/knock-in, and pharmacological manipulations.
Is glutamatergic transmission altered in phenylketonuria?
Yes, impaired glutamatergic synaptic transmission is observed in the PKU brain, contributing to neurological dysfunction.
How does development affect glutamatergic transmission?
During development, glutamatergic synaptic transmission increases in layer II/III mouse motor cortex pyramidal neurons, reflecting maturation of excitatory circuits.
What is the role of N-acetylcysteine in glutamatergic transmission?
N-acetylcysteine modulates glutamatergic transmission and restores synaptic plasticity, showing neuroprotective effects in psychiatric and neurodegenerative disorders.
Conclusion
Glutamatergic synaptic transmission (GO:0035249) is a cornerstone of excitatory signaling in the nervous system, with critical roles in development, plasticity, and disease. Dysregulation of this process is implicated in Alzheimer's disease, phenylketonuria, stress-related disorders, and neuroinflammation. Understanding the genes and mechanisms that control glutamatergic transmission is essential for developing targeted therapies. EDITGENE offers comprehensive CRISPR services to facilitate precise genetic studies of this pathway, empowering researchers to uncover causal relationships and accelerate translational discoveries.
References
- 1. Chakraborty S et al.. 2025. The neuroprotective effects of N-acetylcysteine in psychiatric and neurodegenerative disorders: From modulation of glutamatergic transmission to restoration of synaptic plasticity.. Neuropharmacology 278:110527 PMID: 40414419
- 2. Zott B et al.. 2023. Impairments of glutamatergic synaptic transmission in Alzheimer's disease.. Semin Cell Dev Biol 139:24-34 PMID: 35337739
- 3. Martynyuk AE et al.. 2005. Impaired glutamatergic synaptic transmission in the PKU brain.. Mol Genet Metab 86 Suppl 1:S34-42 PMID: 16153867
- 4. Burnsed J et al.. 2023. Increased glutamatergic synaptic transmission during development in layer II/III mouse motor cortex pyramidal neurons.. Cereb Cortex 33(8):4645-4653 PMID: 36137566
- 5. Greenhalgh A et al.. 2021. Bacterial endotoxin lipopolysaccharide enhances synaptic transmission at low-output glutamatergic synapses.. Neurosci Res 170:59-65 PMID: 32987087
- 6. Lur G et al.. 2019. Ketamine disrupts neuromodulatory control of glutamatergic synaptic transmission.. PLoS One 14(3):e0213721 PMID: 30865708
- 7. McElligott ZA et al.. 2009. Modulation of glutamatergic synaptic transmission in the bed nucleus of the stria terminalis.. Prog Neuropsychopharmacol Biol Psychiatry 33(8):1329-35 PMID: 19524008
- 8. Rao S et al.. 2024. RhoGEF Tiam2 Regulates Glutamatergic Synaptic Transmission in Hippocampal CA1 Pyramidal Neurons.. eNeuro 11(7) PMID: 38871458
